Podcast

Gaining Ground in GI Cancers in Denver

Author(s):

Onclive Team

We traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty.

We recently traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty. Meeting topics spanned the importance of molecular testing in the management of newly diagnosed metastatic colorectal cancer, advances with biomarker-directed therapies and immunotherapies in the relapsed/refractory setting, and the role of tumor sidedness in the treatment of the disease. Experts also highlighted novel approaches being explored in pancreatic cancer, data with immunotherapy in gastric and gastroesophageal junction cancer, and novel investigational agents in hepatocellular carcinoma.

Related Videos
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Related Content
Squamous cell anal carcinoma | Image Credit: © Anatomy Insider - stock.adobe.com
December 20th 2024

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

D. Ross Camidge, MD, PhD and Mary Redman, PhD
December 18th 2024

Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD

FDA
December 18th 2024

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

Andre Henri Goy, MD
December 18th 2024

Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD

Michael J. Pishvaian, MD, PhD, director, Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, associate professor of Oncology, Johns Hopkins Medicine
December 13th 2024

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

FDA
December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma